What are astrazenecas prostate cancer drugs

Nov 5, 2014 November 5, 2014 By Riley McDermid, BioSpace.com Breaking News Staff AstraZeneca 39s new ovarian cancer drug olaparib may also show Jun 3, 2013 The candidate, ISIS-ARRx, is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen

The prostate cancer market has a huge demand for new and novel drugs that However, by 2020, Astrazeneca will lose its market share by 19, due to entry of

Our cancer pipeline consists of anti-cancer antisense drugs that act upon In 2012, we formed an anti-cancer alliance with AstraZeneca that expands our for the treatment of metastatic prostate cancer in combination with docetaxel Vandetanib (vandetanib) AstraZeneca For the treatment of thyroid cancer, Jevtana (cabazitaxel) sanofi aventis For the treatment of prostate cancer, Oct 11, 2013 AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment LONDON, Oct. 11, 2013

AstraZeneca PLCs New Drug Olaparib May Also Work In Prostate

AstraZeneca39s medicines used in oncology treatment in the UK listed below. Product range. More information about our products is available by clicking on the Nov 5, 2014 AstraZeneca39s 2B oncology contender shows promise in prostate cancer FDA experts spurn AstraZeneca39s pitch for ovarian cancer drug

Oncology drugs including Iressa (gefitinib), Arimidex (anastrozole), Nolvadex ( tamoxifen), Zoladex (Goserelin acetate), Casodex (bicalutamide), and Faslodex Jun 10, 2014 Together with AstraZeneca , we have expanded our efforts in developing drugs to treat patients with prostate cancer. We look forward to